| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6201604 | Ophthalmology | 2014 | 7 Pages |
Abstract
Most ranibizumab-treated eyes did not experience sustained preinjection IOP of 21 mmHg or more (>2 consecutive visits) over 24 months. When evaluating the combined IOP end point, more ranibizumab-treated eyes had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more, with concurrent highest IOPs of 21 mmHg or more and 25 mmHg or more versus sham or PDT. Intraocular pressure should be monitored in eyes receiving ranibizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sophie J. MD, Darius M. MD, Steve PhD, Amy Chen MS, Daniel S. MD, PhD, Paul P. MD, Carol MS, Roman G. MD, Phillip MD,